References
- Agelink MW, Sayar K, Klieser E. Usefulness of heart rate variability (HRV) for monitoring clozapine plasma levels. Pharmacopsychiatry 2003; 36(4): 166–7.
- Eschweiler GW, Bartels M, Langle G, Wild B, Gaertner I, Nickola M. Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine. Pharmacopsychiatry 2002; 35(3): 96–100.
- Rajji TK, Uchida H, Ismail Z, Ng W, Mamo DC, Remington G, et al. Clozapine and global cognition in schizophrenia. J Clin Psychopharmacol 2010; 30(4): 431–6.
- McKean A, Vella-Brincat J, Begg E. Prescribing and monitoring clozapine in Christchurch. Australas Psychiatry 2008; 16(4): 263–7.
- Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84(3): 417–23.
- Sternieri E, Pinetti D, Coccia CP, Leone S, Bertolini A, Ferrari A. Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients. J Headache Pain 2005; 6(4): 319–21.
- Lee ST, Ryu S, Nam HJ, Lee SY, Hong KS. Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients. Int Clin Psychopharmacol 2009; 24(3): 139–44.
- Qiu XW, Fu PX, Wang CY, Liu M, Zhou TY, Lu W. Population pharmacokinetics research of clozapine in Chinese schizophrenic patients. Yao Xue Xue Bao 2009; 44(7): 785–92.
- Raedler TJ, Hinkelmann K, Wiedemann K. Variability of the in vivo metabolism of clozapine. Clin Neuropharmacol 2008; 31(6): 347–52.
- Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2000; 49(1): 59–63.
- Tang YL, Mao P, Li FM, Li W, Chen Q, Jiang F, et al. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol 2007; 64(1): 49–56.
- Raedler TJ, Hinkelmann K, Wiedemann K. Variability of the in vivo metabolism of clozapine. Clin Neuropharmacol 2008; 31(6): 347–52.
- Balibey H, Basoglu C, Lundgren S, Babaoglu MO, Yasar U, Herken H, et al. CYP1A2*1F polymorphism decrease clinical response to clozapine in patients with schizophrenia. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2011; 21(2): 93–9.
- Wohlfarth A, Toepfner N, Hermanns-Clausen M, Auwarter V. Sensitive quantification of clozapine and its main metabolites norclozapine and clozapine-N-oxide in serum and urine using LC-MS/MS after simple liquid-liquid extraction work-up. Anal Bioanal Chem 2011; 400(3): 737–46.